Incannex Completes Positive Pre-IND Meeting With FDA On CBD-Based Drug For Treatment Of Rheumatoid Arthritis
Portfolio Pulse from Vuk Zdinjak
Incannex Healthcare Limited (NASDAQ:IXHL) has completed a pre-Investigational New Drug Application (‘pre-IND’) meeting with the U.S. Food and Drug Administration for its proprietary drug product IHL-675A for treatment of rheumatoid arthritis. The FDA provided valuable feedback and confirmed that no further nonclinical studies are needed for the IND application. Incannex is incorporating this guidance into clinical trial designs and the overarching strategy for development of IHL-675A.
July 26, 2023 | 2:56 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Incannex's successful pre-IND meeting with the FDA for its drug IHL-675A could potentially expedite the drug's development and approval process, which may positively impact the company's stock in the short term.
The FDA's positive feedback and confirmation that no further nonclinical studies are needed for the IND application could potentially expedite the drug's development and approval process. This could lead to an increase in investor confidence and a potential rise in Incannex's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100